RenovoRx Inc (NASDAQ:RNXT) — Market Cap & Net Worth
Market Cap & Net Worth: RenovoRx Inc (RNXT)
RenovoRx Inc (NASDAQ:RNXT) has a market capitalization of $78.07 Million ($78.07 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #20272 globally and #4617 in its home market, demonstrating a -13.28% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying RenovoRx Inc's stock price $1.73 by its total outstanding shares 45129508 (45.13 Million). Also see RenovoRx Inc balance sheet assets for a full breakdown of the balance sheet.
RenovoRx Inc Market Cap History: 2021 to 2026
RenovoRx Inc's market capitalization history from 2021 to 2026. Data shows change from $218.43 Million to $78.07 Million (-24.67% CAGR). Also see RenovoRx Inc operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
RenovoRx Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #580 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #1953 of 3165 |
Weight: RenovoRx Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
RenovoRx Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how RenovoRx Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check RenovoRx Inc stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
33.76x
RenovoRx Inc's market cap is 33.76 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $58.22 Million | $43.00K | -$8.81 Million | 1353.89x | N/A |
| 2025 | $37.91 Million | $1.12 Million | -$11.17 Million | 33.76x | N/A |
Competitor Companies of RNXT by Market Capitalization
Companies near RenovoRx Inc in the global market cap rankings as of September 18, 2026. Review RNXT tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to RenovoRx Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
RenovoRx Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, RenovoRx Inc's market cap moved from $218.43 Million to $ 78.07 Million, with a yearly change of -24.67%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $78.07 Million | +105.93% |
| 2025 | $37.91 Million | -34.88% |
| 2024 | $58.22 Million | -43.67% |
| 2023 | $103.35 Million | -2.55% |
| 2022 | $106.05 Million | -51.45% |
| 2021 | $218.43 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of RenovoRx Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $78.07 Million USD |
| MoneyControl | $78.07 Million USD |
| MarketWatch | $78.07 Million USD |
| marketcap.company | $78.07 Million USD |
| Reuters | $78.07 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About RenovoRx Inc
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded i… Read more